Cell and gene therapies
-
Sydney CAR T trial turns fatal
- 19 May 2021
EXCLUSIVE: First death associated with a CAR T-cell trial occurs at Sydney’s Westmead Hospital following use of a non-viral vector. Two patients developed lymphoma.
Read more -
CAR T, genetic test prep for MSAC
- 17 May 2021
Gilead’s Tecartus moves into regulatory processes as a game-changing genetic panel test gets its third shot at MSAC approval, potentially saving $6,683 per patient.
Read more -
Aust in new Zolgensma trial
- 28 Apr 2021
One of four sites named globally where Novartis will trial its gene therapy in children as old as eight with spinal muscular atrophy.
Read more -
Gilead unravels CAR T delay mystery
- 26 Apr 2021
Yescarta was recommended 15 months ago but disappeared. Gilead boss Jaime McCoy reveals how the black hole of MSAC ate the cell therapy.
Read more -
Gene therapies Hunt’s great challenge, says Wilson
- 14 Apr 2021
Designing payment models for gene ‘cures’ is going to mark Greg Hunt’s tenure as Health Minister, PBAC chair Andrew Wilson tells MedNews.
Read more -
Novartis’ 50/50 gene payment plan
- 14 Apr 2021
New gene therapy Luxturna for ultra-rare vision loss offered on a pay-for-performance deal, with half the cost paid upfront.
Read more -
The 10 most expensive drugs
- 14 Apr 2021
What are the most expensive drugs in the US and how many are here in Australia?
Read more -
Cell Therapies appoints CEO
- 07 Apr 2021
Healthcare executive steps up to lead Australian cell and gene therapy manufacturer.
Read more